NPPA fixes retail price of 28 formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 28 formulations, including those used to prevent heart attack and stroke in the future and to treat chest pain (angina), heart failure, and high blood pressure, seizures, and type 2 diabetes, asthma.These include...
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 28 formulations, including those used to prevent heart attack and stroke in the future and to treat chest pain (angina), heart failure, and high blood pressure, seizures, and type 2 diabetes, asthma.
These include Sun Pharma's Cyclosporine Ophthalmic Solution which is used to increase tear production in people with dry eye disease, Zydus Healthcare's Glycopyrronium plus Formoterol Fumarate plus Budesonide Powder for Inhalation.
In addition to this, the list also includes Alkem Healthscience and Alkem Laboratories' Amoxicillin plus Potassium Clavulanate Oral Suspension IP, Ravenbhel Healthcare and Sun Pharma Laboratories' Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet, Windlas Biotech and Torrent Pharmaceuticals' Atorvastatin plus Clopidogrel plus Aspirin Capsule.
Further, the list contains Acetylcysteine plus Acebrophylline Tablet manufactured and marketed by Pure and Cure Healthcare and Cipla limited, Levetiracetam Tablet IP manufatured and marketed by Pure and Cure Healthcare and Mankind Pharma.
This price fixation is followed by the decisions made by the National Pharmaceutical Pricing Authority at its 94th Authority meeting held on 23rd December 2021, where the Authority discussed new drug application price fixation under para 5 and para 15 of DPCO 2013.
This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Cyclosporine Ophthalmic Solution | Each ml contains: Cyclosporine IP 0.9mg Aqueous Buffered Vehicle q.s. | Each 0.25ml Pack | M/s Sun Pharmaceutical Industries Limited | 51.29 |
2. | Amoxicillin + Potassium Clavulanate Oral Suspension IP | Each 5ml of reconstituted suspension contains: Amoxicillin Trihydrate eq. to Amoxicillin IP 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg | 1 ML | M/s Alkem Healthscience / M/s Alkem Laboratories Ltd. | 3.36 |
3. | Povidone- Iodine + Ornidazole Ointment | Composition: Povidone-Iodine IP 5%w/w (Available Iodine 0.5%w/w) Ornidazole IP 1% w/w In an Ointment base | 1 gm | M/s Innova Captab Ltd. / M/s Emcure Pharmaceuticals Ltd. | 3.78 |
4. | Povidone | Each 100ml solution | Each | M/s GS | 230.00 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Iodine Topical Solution | contains: Povidone Iodine IP 1.0g (Available Iodine 0.1 g) 2-Propanol IP 50g | Pack (500ml) | Pharmabutor Pvt. Ltd. / M/s Win Medicare Pvt. Ltd. | ||
5. | Atorvastatin + Clopidogrel Capsule | Each hard gelatin capsule Contains: Atorvastatin Calcium IP eq to Atorvastatin 40mg (As green coloured spherical pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two brown coloured film coated tablets Each containing 37.5mg Clopidogrel Tablets IP) | 1 Capsule | M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd. | 28.08 |
6. | Diclofenac Diethylamine + Methyl Salicylate + Menthol Gel | Gel contains: Diclofenac Diethylamine IP 2.32% w/w (equivalent to Diclofenac Sodium IP 2.0% w/w) Methyl Salicylate IP 10% w/w Menthol IP 5% w/w | 1 gm | M/s Tuton Pharmaceuticals /M/s Unison Pharmaceuticals Pvt. Ltd. | 3.69 |
7. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 6.25mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Sun Pharma Laboratories Limited | 9.86 |
8. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 6.25mg Metoprolol Succinate | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Sun Pharma Laboratories Limited | 10.81 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | |||||
9. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As coloured pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two brown coloured film coated tablet each containing 37.5mg clopidogrel tablet IP), Aspirin IP 75mg (As enteric coated white coloured pellets) | 1 Capsule | M/s Windlas Biotech Limited / M/s Torrent Pharmaceuticals Limited | 12.92 |
10. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As coloured pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated tablet each containing 37.5mg clopidogrel tablet IP), Aspirin IP 75mg (As enteric coated white coloured pellets) | 1 Capsule | M/s Windlas Biotech Pvt. Ltd. / M/s USV Pvt. Ltd. | 12.92 |
11. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 6.25mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Lupin Limited | 9.86 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
25mg | |||||
12. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 6.25mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Lupin Limited | 10.81 |
13. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 12.50mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Lupin Limited | 11.92 |
14. | Telmisartan, Chlorthalidone & Metoprolol (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 12.50mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. /M/s Lupin Limited | 10.88 |
15. | Diclofenac injection IP | Each ml contains: Diclofenac Sodium IP 75mg Water for injection IP | 1 ml | M/s Nitin Lifesciences Ltd./ M/s Modi- Mundipharma Pvt. Ltd. | 20.27 |
16. | Amoxycillin + Potassium Clavulanate Oral Suspension IP | Each 5ml of the reconstituted suspension contains: Amoxycillin Trihydrate eq. to Amoxycillin IP 400mg Potassium Clavulanate | 1 ml | M/s Associated Biotech./ M/s Eris Healthcare Pvt. Limited | 3.68 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Diluted IP eq. to Clovulanic Acid 57mg | |||||
17. | Mefenamic Acid+ Tranexamic Acid Tablet | Each film coated tablet contains: Mefenamic Acid IP 250mg Tranexamic Acid IP 500mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Eris Healthcare Pvt. Limited | 26.12 |
18. | Atorvastatin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured spherical pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two brown coloured film coated tablets Each containing 37.5mg Clopidogrel Tablets IP), | 1 Capsule | M/s Windlas Biotech Limited / M/s Torrent Pharmaceuticals Limited | 28.08 |
19. | Glimepiride + Metformin Hydrochloride + (Sustained Release) + Voglibose Tablet | Each uncoated bilayer tablet contains : Glimepiride IP - 1 mg Metformin Hydrochloride IP - 500 mg (Sustained Release Form) Voglibose IP - 0.2 mg | 1 Tablet | M/s Theon Pharmaceuticals Limited / M/s FDC Limited | 9.82 |
20. | Metoprolol Succinate prolonged Released Tablets IP | Each film coated prolonged release tablet contains: Metoprolol Succinate IP 95mg eq. to Metoprolol Tartrate 100mg | 1 Tablet | M/s Micro Labs Limited | 11.38 |
21. | Glimepiride + Metformin Hydrochloride + (Sustained Release) + Voglibose Tablet | Each uncoated bilayer tablet contains : Glimepiride IP - 2 mg Metformin Hydrochloride IP - 500 mg (Sustained Release Form) Voglibose IP - 0.2 mg | 1 Tablet | M/s Theon Pharmaceuticals Limited / M/s FDC Limited | 12.50 |
22. | Clobazam | Each uncoated Mouth | 1 Tablet | M/s Pure & Cure | 2.54 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Mouth Dissolving tablet | Dissolving tablet contains: Clobazam IP 2.5mg | Healthcare Pvt. Ltd. / M/s Intas Pharmaceuticals Limited | |||
23. | Acetylcysteine + Acebrophylline Tablet | Each film coated tablet contains: Acetylcysteine BP 600mg Acebrophylline 100mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/ Cipla limited | 12.48 |
24. | Levetiracetam Tablet IP | Each film coated tablet contains: Levetiracetam IP 1000mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd. | 29.87 |
25. | Levetiracetam Tablet IP | Each film coated tablet contains: Levetiracetam IP 1000mg | 1 Tablet | M/s Swiss Garnier Genexiaa Sciences Pvt. Ltd. / M/s Wockhardt Limited | 26.70 |
26. | Glycopyrronium + Formoterol Fumarate + Budesonide Powder for Inhalation | Each capsule contains: Glycopyrrolate IP eq. to Glycopyrronium 25mcg Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 12mcg Budesonide IP 400mcg | 1 Capsule | M/s Zydus Healthcare Limited | 12.64 |
27. | Esomeprazole + Domperidone SR Capsule | Each hard Gelatin Capsule Contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40mg (as gastro-resistant pellets) Domperidone IP 30mg (as sustained release pellets) | 1 Capsule | M/s Indu Drugs Private Limited | 10.70 |
28. | Atorvastatin + Clopidogrel Capsule | Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green | 1 Capsule | M/s Windlas Biotech Limited / M/s Zydus Healthcare Ltd. | 30.74 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
coloured spherical pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two brown coloured film coated tablets Each containing 37.5mg Clopidogrel Tablets IP), |
The notification further added;
(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
To view the official notice, click the link below:
https://www.nppaindia.nic.in/wp-content/uploads/2021/12/Retail_English.pdf
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd